roch acquir spark februari spark report
enter definit merger agreement roch fulli acquir
price per share all-cash transact per share price
repres premium spark close price februari
merger agreement unanim approv
board compani transact expect close
cs thought deal outlin earlier note roch may
spark anoth bull gene therapi name transact valu
suggest roch see like re-emerg spark hemophilia gene
therapi program substanti opportun assign
addit pipelin program pomp
technolog platform rel assumpt acquir may view
spark hemophilia program stronger competit posit
current see substanti higher po market share agre
view consider potenti upsid hemophilia gene
therapi opportun emerg market see hem gene therapi
pois go prime-time note see signific ad valu
indic anoth potenti acquir involv process given
high impli premium see likelihood higher bid low though
could see strateg fit across mani hemophilia/gen therapi competitor
novarti sanofi believ unlik
roche/spark deal draw materi anti-trust issu
increas tp maintain neutral rate
increas tp in-lin propos offer roch ep
unchang upsid risk thesi includ potenti competit bid
compani downsid risk includ failur deal close clinic
regulatori commerci headwind
valuat metric
number share
price month
 close
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
spark biotechnolog compani focus
develop commerci gene therapi treatment
price feb rate neutral target price analyst martin auster
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
 close
blue sky valuat base propos roch
fail develop/identifi competit product profil spk-
lose pipeline/technolog valu face
reimburs challeng luxturna
compani mention price
